Nobilis Therapeutics is developing proprietary inhalation-based therapeutics using controlled self-administration of inert gases to address unmet medical need in the treatment of psychiatric and neurodegenerative diseases.

By leveraging data on more than 500 patients successfully treated for conditions ranging from panic disorder to autoimmune diseases, Nobilis has coupled its patent pending gas mixtures with a proprietary inhalational device to offer reproducible, standardized, and controlled patient exposure. The Company is currently advancing its technologies into human clinical trials.

Twitter Feed

Nobilis Therapeutics @NobilisTx
Nmda receptors critical to social interaction Xenon modulates nmda receptors https://t.co/VJ53Ai2125
h J R
Nobilis Therapeutics @NobilisTx
RT @electroboyusa: #PTSD is estimated to affect about 1 in every 3 people who have a traumatic experience @Healthy_Minds @sharon4marie @mhm…
h J R
Nobilis Therapeutics @NobilisTx
RT @HarvardChanSPH: "We believe that genetic variation is an important factor contributing to [PTSD] risk or resilience." https://t.co/rgbp
h J R
Nobilis Therapeutics @NobilisTx
RT @BatuBiologics: publication with Dr Santosh Kesari of John Wayne Cancer Institute showing mechanisms of Vallovax #cancer therapy https:…
h J R